| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|
| Revenue | ||||
| Cost of revenue | ||||
| Operating income | ||||
| Operating margin | ||||
| Net income | ||||
| Net profit margin | ||||
| Cash on hand | ||||
| Change in cash | ||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 48.20 mm | 48.20 mm | 48.20 mm | 48.20 mm | 48.20 mm | 48.20 mm |
| Cash burn (monthly) | 3.75 mm | 556.33 k | 4.41 mm | 3.57 mm | 2.79 mm | 3.20 mm |
| Cash used (since last report) | 18.98 mm | 2.82 mm | 22.33 mm | 18.08 mm | 14.15 mm | 16.18 mm |
| Cash remaining | 29.22 mm | 45.38 mm | 25.87 mm | 30.12 mm | 34.05 mm | 32.02 mm |
| Runway (months of cash) | 7.8 | 81.6 | 5.9 | 8.4 | 12.2 | 10.0 |
| 13F holders | Current |
|---|---|
| Total holders | 81 |
| Opened positions | 16 |
| Closed positions | 26 |
| Increased positions | 28 |
| Reduced positions | 19 |
| 13F shares | Current |
|---|---|
| Total value | 26.87 bn |
| Total shares | 83.08 mm |
| Total puts | 27.60 k |
| Total calls | 700.00 |
| Total put/call ratio | 39.4 |
| Largest owners | Shares | Value |
|---|---|---|
| Biotechnology Value Fund L P | 6.23 mm | $3.74 mm |
| Frazier Life Sciences Management | 5.99 mm | $3.60 bn |
| Tang Capital Management | 4.76 mm | $2.86 bn |
| Tang Capital Partners | 4.30 mm | $12.99 mm |
| Empery Asset Management | 4.00 mm | $2.09 mm |
| GS The Goldman Sachs Group, Inc. | 3.99 mm | $2.39 bn |
| Farallon Capital Management | 3.53 mm | $2.12 bn |
| Logos Global Management | 3.50 mm | $2.10 mm |
| Frazier Life Sciences Public Fund | 3.46 mm | $9.34 mm |
| Farallon Capital Partners | 3.12 mm | $1.87 mm |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 15 Feb 25 | Joseph J Ferra Jr | Common Stock | Payment of exercise | Dispose F | No | No | 0.6717 | 9,211 | 6.19 k | 125,271 |
| 15 Feb 25 | Joseph J Ferra Jr | Common Stock | Option exercise | Acquire M | No | No | 0 | 25,000 | 0.00 | 134,482 |
| 15 Feb 25 | Joseph J Ferra Jr | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 25,000 | 0.00 | 75,000 |
| 15 Feb 25 | Joseph J Ferra Jr | Stock Option Common Stock | Grant | Acquire A | No | No | 0.6717 | 800,000 | 537.36 k | 800,000 |
| 15 Feb 25 | Valerie Malyvanh Jansen | Common Stock | Payment of exercise | Dispose F | No | No | 0.6717 | 5,189 | 3.49 k | 12,311 |
| 15 Feb 25 | Valerie Malyvanh Jansen | Common Stock | Option exercise | Acquire M | No | No | 0 | 17,500 | 0.00 | 17,500 |
| 15 Feb 25 | Valerie Malyvanh Jansen | Stock Option Common Stock | Grant | Acquire A | No | No | 0.6717 | 275,000 | 184.72 k | 275,000 |
| 15 Feb 25 | Tammy Furlong | Common Stock | Payment of exercise | Dispose F | No | No | 0.6717 | 89 | 59.78 | 8,216 |
| 15 Feb 25 | Tammy Furlong | Common Stock | Option exercise | Acquire M | No | No | 0 | 300 | 0.00 | 8,305 |
| 15 Feb 25 | Tammy Furlong | Common Stock | Payment of exercise | Dispose F | No | No | 0.6717 | 2,780 | 1.87 k | 8,005 |
